NCE-1 Intelligence & Market Opportunity

Zilbrysq

Zilucoplan

Immunomodulators

Subcutaneous Injection

Zilbrysq is a once-daily self-administered injection for adults with generalized myasthenia gravis who test positive for anti-AChR antibodies. It blocks the complement C5 protein to reduce muscle weakness and improve strength.

Approval Date

17-Oct-23

NCE-1 Date

17-Oct-27

NCE Date

17-Oct-28

Commercial snapshot

Market performance & projections

Revenue ($M)

244

CAGR (%)

0.2785

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

385

2027

445

2028

546

2029

652

2030

715

2031

775

2032

836

Molecule profile

Details & specifications

Molecule

Zilucoplan

Innovator

UCB INC

Dosage Form

Subcutaneous Injection

Strength

16.6 mg base/0.416 mL, 23 mg base/0.574 mL, 32.4 mg base/0.81 mL

Therapeutic Category

Immunomodulators

Usage

To treat generalized myasthenia gravis in adults who are anti-acetylcholine receptor (AChR) antibody positive

Good to know

Frequently asked questions

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.